VistaGen Therapeutics Inc. (VTGN)
NASDAQ · Healthcare
VistaGen Therapeutics Inc. Shareholder Equity 2011–2025
VistaGen Therapeutics Inc. annual shareholder equity history from 2011 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- VistaGen Therapeutics Inc. shareholder equity as of March 31, 2025: 70.4M, a 38.41% decrease year-over-year.
- VistaGen Therapeutics Inc. shareholder equity for 2025 were 70.4M, a 38.41% decrease from 2024.
- VistaGen Therapeutics Inc. shareholder equity for 2024 were 114.3M, a 846.08% increase from 2023.
- VistaGen Therapeutics Inc. shareholder equity for 2023 were 12.1M, a 81.33% decrease from 2022.
- VistaGen Therapeutics Inc. shareholder equity for 2022 were 64.7M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| VistaGen Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $70 |
| 2024 | $114 |
| 2023 | $12 |
| 2022 | $65 |
| 2021 | $92 |
| 2020 | $-6 |
| 2018 | $7 |
| 2017 | $1 |
| 2016 | $-3 |
| 2013 | $-13 |
| 2012 | $-6 |
| 2011 | $-33 |
VistaGen Therapeutics Inc. Shareholder Equity — FAQ
VistaGen Therapeutics Inc. (VTGN) shareholder equity over the last 12 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see VTGN's shareholder equity history?
The chart and table above show VistaGen Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.